The non-prostanoid IP receptor agonist, APD811 (ralinepag) has potent antiproliferative and vasorelaxant properties in human pulmonary artery Source: International Congress 2017 – Experimental PH Year: 2017
In vitro pharmacological profile of SMP-028, a novel potent anti-inflammatory agentSource: Annual Congress 2010 - Models of airways disease Year: 2010
TNFα-induced glucocorticoid resistance: Effect of steroidal and non-steroidal GR agonists, formoterol and inhibition of inflammatory signalling Source: Annual Congress 2012 - Molecular biology of pro- and anti-inflammatory responses in the lung Year: 2012
Anti-inflammatory, antioxidant and immunomodulatory effects of curcumin in sensitized rat Source: International Congress 2017 – Towards better treatments for lung disease: experimental pharmacology Year: 2017
Anti-inflammatory and immunomodulatory potential of Cys LT1 receptor antagonists (LTRA) in steroid dependent persistent asthma Source: Eur Respir J 2005; 26: Suppl. 49, 136s Year: 2005
Do long-acting β2-adrenoceptor agonists enhance the anti-inflammatory effect of glucocorticoids in asthma? Source: Eur Respir J 2001; 17: 1059-1061 Year: 2001
Effect of long-acting β2 adrenergic receptor agonists and glucocorticoids on extracellular matrix production Source: Eur Respir J 2001; 18: Suppl. 33, 475s Year: 2001
A combination of thyme and ivy exerts potent anti-inflammatory and mucus-normalizing activity in vivo and inhibits 5-LO and PDE4 Source: International Congress 2014 – Animal models in respiratory drug development Year: 2014
LATE-BREAKING ABSTRACT: GW870086: A potent anti-inflammatory glucocorticoid with a novel pharmacological profile Source: Annual Congress 2013 –Hot topics on airway diseases: new horizons in treatment Year: 2013
Enhanced endothelial barrier protective and anti-inflammatory effects by synthetic iloprost-conjugated phospholipid. Source: International Congress 2018 – Triggers of acute lung injury: mechanical ventilation and oxygen levels Year: 2018
In vitro pharmacological characterization of the novel inhaled bronchodilator CHF6366 acting as dual muscarinic antagonist/ß2-agonist (MABA) Source: International Congress 2017 – Bronchodilators and bronchoprotectors Year: 2017
Novel anti-inflammatory agents Source: Annual Congress 2009 - Emerging trends in the therapy of COPD Year: 2009
In vitro pharmacological profile of CHF 5407, a potent, long-acting and selective muscarinic M3 receptor antagonistSource: Eur Respir J 2007; 30: Suppl. 51, 25s Year: 2007
Anti-inflammatory efficacy of formoterol via transrepressive mechanisms is independent of the glucocorticoid receptor in human bronchial epithelial cells Source: Eur Respir J 2004; 24: Suppl. 48, 128s Year: 2004
Synergistic action of the anticholinergic r,r-glycopyrrolate with glucocorticoids and PDE4-inhibitors Source: Eur Respir J 2005; 26: Suppl. 49, 217s Year: 2005
The in vitro biology of Compound X – a novel β2 adrenoceptor agonist with a long duration of action Source: Annual Congress 2008 - Novel treatments for respiratory disease Year: 2008
Targeting neuropeptide receptors by substance-P analogues identifies a strategy to develop novel anti-cancer therapies Source: Annual Congress 2008 - Therapy of thoracic tumours Year: 2008
PKA/cAMP-independent transactivation of glucocorticoid receptor by long acting β2 agonists Source: Eur Respir J 2006; 28: Suppl. 50, 103s Year: 2006
Glycosaminoglycan synthesis is modulated by glucocorticoids and beta2 -adrenergic agonists Source: Eur Respir J 2004; 24: Suppl. 48, 95s Year: 2004
Pharmacological profile of a novel, potent and oral TRPA1 antagonist. Characterization in a preclinical model of induced cough Source: International Congress 2015 – Novel treatments for cough, asthma, COPD and bronchiectasis Year: 2015